Skip to content

Author

S. Chandarlapaty

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

CDKPredict: a clinicogenomic model for risk-adapted therapeutic intervention in breast cancer

Wide variation in outcomes is observed for patients with hormone-receptor-positive metastatic breast cancer (MBC) receiving first-line CDK4/6 inhibitors plus endocrine therapy (CDK4/6i+ET). Although front-line escalation strategies are beginning to enter clinical practice, assigning patients to intensified or de-intens...

L. Boscolo Bielo, F. Sánchez-Vega, Subhiksha Nandakumar et al. · 0 citations
Open access Aug 2026

Rb-driven transcription limits its tumour-suppressive effects in breast cancer

The retinoblastoma protein (Rb) is a tumour suppressor best known for repressing E2F transcription factors and halting cell cycle progression1. In hormone receptor-positive (HR+) breast cancer, CDK4/6 inhibitors activate Rb by preventing its phosphorylation, forming a key component of current endocrine therapy regimens...

April C. Watt, Antonio Ahn, Catherine Blyth et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.